In vivo extrastriatal and striatal D2 dopamine receptor blockade by amisulpride in schizophrenia.
Amisulpride, a substituted benzamide with high affinity for dopamine D2 and D3 receptors only, has been reported to have therapeutic effects on both negative and positive schizophrenic symptoms, although at distinct dose ranges (50-300 mg/day vs. 400-1,200 mg/day). The purpose of this study was to investigate the binding of amisulpride to extrastriatal (i.e., thalamus and temporal cortex) and striatal D2 dopamine receptors with respect to plasma amisulpride determinations. Ten patients with schizophrenia treated with amisulpride over a wide range of doses (25-1,200 mg/day) were studied. Positron emission tomography images were acquired by using 76Br-FLB-457, a highly specific antagonist of the D2 and D3 dopamine receptors. Binding indexes (BI) in the regions studied were estimated with reference to values from six healthy subjects. A curvilinear relationship was demonstrated between plasma concentration of amisulpride and the BI in extrastriatal regions. The BI also varied as a function of plasma concentration in striatum. Furthermore, the data provide evidence for different binding profiles: low plasma concentrations (28-92 ng/mL) induced marked extrastriatal binding and low striatal binding, whereas higher plasma concentrations (>153 ng/mL) induced marked binding both in extrastriatal and striatal regions. Dose-dependent differential binding profiles of amisulpride to D2 receptors in extrastriatal and striatal regions were demonstrated, and two therapeutic ranges of plasma concentrations for negative and positive schizophrenic symptoms, respectively, are suggested.
Xiberas
X
X
INSERM U334, Service Hospitalier Frédéric Joliot, DSV-DRM-CEA, Orsay, France.
Martinot
J L
JL
Mallet
L
L
Artiges
E
E
Canal
M
M
Loc'h
C
C
Mazière
B
B
Paillère-Martinot
M L
ML
D000328:Adult; D000077582:Amisulpride; D014150:Antipsychotic Agents / Q000378:metabolism* / Q000627:therapeutic use; D003342:Corpus Striatum / Q000378:metabolism*; D018492:Dopamine Antagonists / Q000494:pharmacology; D065127:Dopamine D2 Receptor Antagonists; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011759:Pyrrolidines / Q000494:pharmacology; D017448:Receptors, Dopamine D2 / Q000378:metabolism; D012457:Salicylamides / Q000494:pharmacology; D012559:Schizophrenia / Q000097:blood* / Q000000981:diagnostic imaging / Q000188:drug therapy; D018709:Statistics, Nonparametric; D013469:Sulpiride / Q000031:analogs & derivatives* / Q000378:metabolism* / Q000627:therapeutic use; D013702:Temporal Lobe / Q000378:metabolism*; D013788:Thalamus / Q000378:metabolism*; D014055:Tomography, Emission-Computed
D014150:Antipsychotic Agents; D018492:Dopamine Antagonists; D065127:Dopamine D2 Receptor Antagonists; D011759:Pyrrolidines; D017448:Receptors, Dopamine D2; D012457:Salicylamides; C065065:FLB 457; D013469:Sulpiride; D000077582:Amisulpride